Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

计划入组 2 人 · 首次发布于 2021 年 5 月 28 日

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

计划入组 35 人 · 首次发布于 2019 年 9 月 9 日

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

计划入组 81 人 · 首次发布于 2014 年 2 月 3 日

Dostarlimab(Jemperli)

MASH(Repair)

LGR6 modulators (wound repair)

Tissue Repair Ltd

Phoenix Tissue Repair, Inc.

United States

HEART REPAIR TECHNOLOGIES, INC.

United States

Dostarlimab Shows Promise in Eliminating Need for Surgery Across Multiple dMMR Cancer Types

Immunotherapy Alone Achieves Complete Response in Mismatch Repair-Deficient Gastroesophageal Junction Cancer, Sparing Patient from Chemotherapy and Surgery

INSPIRE Trial: Nivolumab and Ipilimumab Show Promise in Mismatch Repair-Deficient Metastatic Prostate Cancer